Myriad Genetics MYGN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70%0.0pp | 69.9%-0.4pp | 70.4%-0.1pp | 70.4%+0.4pp | 70%+0.1pp | |
| Operating margin | -46.9%0.0pp | -47%+4.0pp | -51%-0.9pp | -50.1%-35.1pp | -15%-0.2pp | |
| Net margin | -48.2%-3.9pp | -44.4%+4.1pp | -48.5%-1.1pp | -47.4%-35.3pp | -12.2%+3.0pp | |
| EBITDA margin | -40.7%-0.2pp | -40.4%+3.7pp | -44.2%-1.2pp | -43%-35.2pp | -7.8%-0.3pp | |
| Returns | ||||||
| Return on equity | -76.7%-8.3pp | -68.5%+4.1pp | -72.5%-2.5pp | -70%-56.2pp | -13.8%+3.3pp | |
| Return on assets | -47.6%-5.4pp | -42.2%+2.1pp | -44.3%+0.6pp | -44.8%-35.3pp | -9.6%+2.1pp | |
| Return on invested capital | -65.7%+1.3pp | -67%+3.4pp | -70.4%-3.2pp | -67.2%-51.3pp | -15.9%+0.3pp | |
| Efficiency | ||||||
| Asset turnover | 1×0.0× | 1×0.0× | 0.9×0.0× | 0.9×+0.2× | 0.8×0.0× | |
| Inventory turnover | 8.9×+0.3× | 8.5×+0.1× | 8.5×-0.5× | 9×-0.4× | 9.4×-0.8× | |
| Liquidity | ||||||
| Current ratio | 2.4×-0.1× | 2.5×+0.2× | 2.3×+0.9× | 1.4×-0.5× | 1.9×+0.1× | |
| Quick ratio | 2.2×-0.1× | 2.3×+0.1× | 2.1×+0.8× | 1.3×-0.4× | 1.7×+0.1× | |
| Cash ratio | 1×-0.2× | 1.1×+0.1× | 1×+0.6× | 0.4×-0.2× | 0.7×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×+0.1× | 0.6×0.0× | 0.6×+0.2× | 0.4×+0.2× | 0.2×0.0× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.2×+0.1× | 0.2×0.0× | |
| Interest coverage | -28.2×+8.7× | -36.9×+25.0× | -61.8×+48.0× | -109.8×-69.6× | -40.2×+3.9× | |
| Per Share | ||||||
| Book value per share | $3.60-9.4% | $3.97-0.8% | $4.00-4.6% | $4.20-45.6% | $7.71-0.3% | |
| Valuation | ||||||
| Market capitalization | $512.85M+13.1% | $573.26M-14.8% | $672.71M+44.5% | $465.5M-42.5% | $809.91M-35.1% | |
| Enterprise value | $598.35M+17.3% | $631.76M-13.5% | $730.21M+36.1% | $536.4M-38.1% | $866.51M-32.1% | |
| Price / sales | 0.6×+0.1× | 0.7×-0.1× | 0.8×+0.3× | 0.6×-0.4× | 1×-0.5× | |
| Price / book | 1.5×+0.9× | 1.6×-0.2× | 1.8×+0.6× | 1.2×+0.1× | 1.1×-0.6× | |
| EV / sales | 0.7×+0.1× | 0.8×-0.1× | 0.9×+0.2× | 0.6×-0.4× | 1×-0.5× | |
| Earnings yield | -78%-55.6pp | -63.8%-4.3pp | -59.5%+25.4pp | -84.9%-72.4pp | -12.5%-2.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Myriad Genetics's profit margins?
- Myriad Genetics (MYGN) runs a 70.0% gross margin and a -46.9% operating margin, with a -48.2% net margin.
- Where do Myriad Genetics's ratios come from?
- Every ratio is computed from Myriad Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
